Celldex Therapeutics

Latest Headlines

Latest Headlines

Promising glioblastoma data spur Celldex shares

Shares of Celldex Therapeutics shot up after a team of top researchers achieved prominent attention for some impressive mid-stage clinical trial results for a new therapeutic vaccine designed to

Pfizer returns brain cancer vax rights to Celldex

Pfizer is returning the rights to rindopepimut (CDX-110), a therapeutic cancer vaccine, to Celldex Therapeutics. Pfizer, which gained rights to the drug as part of $440 million deal in 2008, says

Vax for range of cancers may be available in 5 years

A vaccine that has shown to be effective against breast, bowel and cervical cancers is being tested on some patients and may be available in about five years. The vaccine, which is being developed by

The ASCO roundup: ArQule drug flunks a mid-stage test

Plenty of more early-stage and mid-stage study results came to light at ASCO over the past day. Here are some of the highlights: ArQule said that its lung cancer drug flunked a mid-stage study, but

ASCO: Lilly tracks partial melanoma response, Celldex shares sink

Last night's data dump ahead of ASCO produced a treasure trove of information, but few signs of any dramatic leap or pratfall. Among the highlights: Eli Lilly (NYSE: LLY) reported that a handful of

Cancer vax developers' shares spike on data

Shares of Antigenics surged for three straight days this week after researchers released new data backing its kidney cancer vaccine Oncophage. Investors pushed the stock straight up after hearing

Celldex acquires CuraGen for $94.5M

Massachusetts-based Celldex Therapeutics is paying $94.5 million to acquire CuraGen. Celldex gains CuraGen's portfolio of 11 oncology-focused antibodies. Its most advanced therapy is CR011, which is

Vaccines Technologies, Celldex ink deal

Boston-based Vaccine Technologies (VTI) has inked a license and development agreement with Celldex Therapeutics. VTI will have exclusive licensing rights to Celldex's CholeraGarde and ETEC vaccine

Celldex inks tech deal to advance cancer vaccines

Celldex Therapeutics has struck a deal to use 3M's toll-like receptor (TLR) agonist compounds--useful as vaccine adjuvants--for a slate of new oncology vaccines in development. 3M Drug Delivery

Pfizer, Avant ink $440M cancer vax deal

Avant Immunotherapeutics is pocketing a $40 million upfront fee and a $10 million equity stake from Pfizer in exchange for the worldwide rights to Avant's experimental brain cancer vaccine. And